Patents by Inventor Wanwan YU

Wanwan YU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LRRK2 INHIBITORS
    Publication number: 20230416272
    Abstract: The present invention is directed to compounds of formula I The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.
    Type: Application
    Filed: June 8, 2023
    Publication date: December 28, 2023
    Applicant: H. Lundbeck A/S
    Inventors: Thomas Jensen, Mikkel Jessing, Wanwan Yu, David Rodriguez Diaz, Jacob Nielsen, Christopher Richard Jones, Thomas Andersen, Mikkel Fog Jacobsen
  • LRRK2 inhibitors
    Patent number: 11780851
    Abstract: The present invention is directed to compounds of formula I The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.
    Type: Grant
    Filed: October 26, 2022
    Date of Patent: October 10, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Thomas Jensen, Mikkel Jessing, Wanwan Yu, David Rodriguez Diaz, Jacob Nielsen, Christopher Richard Jones, Thomas Andersen, Mikkel Fog Jacobsen
  • LRRK2 INHIBITORS
    Publication number: 20230144725
    Abstract: The present invention is directed to compounds of formula I The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.
    Type: Application
    Filed: October 26, 2022
    Publication date: May 11, 2023
    Applicant: H. Lundbeck A/S
    Inventors: Thomas Jensen, Mikkel Jessing, Wanwan YU, David Rodriguez Diaz, Jacob Nielsen, Christopher Richard Jones, Thomas Andersen, Mikkel Fog Jacobsen
  • N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS
    Publication number: 20220220095
    Abstract: The present invention provides N-(heteroaryl)methyl)-1-tosyl-1H-pyrazole-3-carboxamide derivatives of the structure Formula (I), which activate the Kv3 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and to the compounds and pharmaceutical compositions thereof for use in methods of medical treatment of disorders responsive to the activation of Kv3 potassium channels, such as e.g. neurological or psychiatric disorders for example epilepsy, schizophrenia, cognitive impairment associated with schizophrenia (CIAS), autism spectrum disorder, bipolar disorder, ADHD, anxiety-related disorders, depression, cognitive dysfunction, Alzheimer's disease, Fragile X syndrome, chronic pain, hearing loss, sleep and circadian disorders, and sleep disruption. Exemplary compounds are e.g.
    Type: Application
    Filed: April 24, 2020
    Publication date: July 14, 2022
    Inventors: Anette Graven SAMS, Lars Kyhn RASMUSSEN, Wanwan YU
  • ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
    Publication number: 20220204489
    Abstract: The present invention provides novel compounds which activate the Kv3 potassium channels. The compounds have the structure (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and use of the compounds to treat disorders responsive to the activation of Kv3 potassium channels.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 30, 2022
    Inventors: Anette Graven SAMS, Lars Kyhn RASMUSSEN, Wanwan YU
  • ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS
    Publication number: 20200131156
    Abstract: The present invention provides novel compounds which activate the Kv3 potassium channels. The compounds have the structure Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and use of the compounds to treat disorders responsive to the activation of Kv3 potassium channels.
    Type: Application
    Filed: October 29, 2019
    Publication date: April 30, 2020
    Inventors: Anette Graven SAMS, Lars Kyhn RASMUSSEN, Wanwan YU, Paul Robert FLEMING